Immunoglobulin E blockade in the treatment of asthma

Robert Kuhn

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Patients with moderate-to-severe asthma often have persistent symptoms despite aggressive pharmacotherapy, enthusiastic patient compliance, and proper technique in using delivery devices. Persistent symptoms have detrimental effects on patients' quality of life and result in a tremendous financial burden because of an increased utilization of health care resources. Guidelines from the National Asthma Education and Prevention Program list symptom prevention, near-normal lung function, and participation in activities (e.g., school, work) as goals of successful asthma therapy. The development of pharmacologic and biologic therapies that target different aspects of airway inflammation will help patients with persistent asthma symptoms achieve these goals. Immunoglobulin E (IgE) is increasingly recognized as a key component of asthma pathophysiology and contributes to both the early- and late-phase inflammatory cascade of the airways by inhibiting allergen-induced activation of mast cells. Both epidemiologic and clinical evidence support the use of IgE blockade for asthma treatment. Omalizumab is currently the only IgE-targeted therapy approved by the United States Food and Drug Administration for asthma treatment. The drug improves symptoms, reduces exacerbations, and improves quality of life in certain patient populations.

Original languageEnglish
Pages (from-to)1412-1424
Number of pages13
Issue number10
StatePublished - Oct 2007


  • Antiinflammatory asthma
  • Corticosteroids
  • Dosing
  • IgE
  • Immunoglobulin E
  • Omalizumab

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Immunoglobulin E blockade in the treatment of asthma'. Together they form a unique fingerprint.

Cite this